Reuters -- Endo Pharmaceuticals Holdings Inc has granted Valeant Pharmaceuticals International an exclusive license to market the pain drug Opana in Canada, Australia and New Zealand for an upfront payment of C$2 million ($1.8 million), the companies said.
